The Ramsay Health Care Limited (ASX: RHC) share price is almost down to its 52-week low price. It’s currently sitting at $62.82. Investors didn’t respond well to the Ramsay report, it’s down 7.3% since then. So, was it that bad? In the report Ramsay revealed that revenue grew by 3%, ‘core’ earnings before interest and tax (EBIT) grew by 1.5%, ‘core’ net profit after tax (NPAT) grew by 7.5%, ‘core’ earnings per share (EPS) grew by 7.8% and statutory EPS declined by 3.6%. The headline figures aren’t incredible, but there’s more to it than it seems. Ramsay is a…
You can continue reading this story now by entering your email below
The Ramsay Health Care Limited (ASX: RHC) share price is almost down to its 52-week low price. It’s currently sitting at $62.82.
Investors didn’t respond well to the Ramsay report, it’s down 7.3% since then.
So, was it that bad?
In the report Ramsay revealed that revenue grew by 3%, ‘core’ earnings before interest and tax (EBIT) grew by 1.5%, ‘core’ net profit after tax (NPAT) grew by 7.5%, ‘core’ earnings per share (EPS) grew by 7.8% and statutory EPS declined by 3.6%.
The headline figures aren’t incredible, but there’s more to it than it seems. Ramsay is a global business, so we have to look at each individual part.
Australian revenue grew by 4.3% and Australian EBIT grew by 9.1%. This is a strong performance compared to fellow private hospital operator Healthscope Ltd’s (ASX: HSO) Australian result.
Ramsay’s equity accounted share of the Asia joint venture net profits was up 24.1% to $8.5 million.
However, Ramsay’s other large international segments didn’t do so well.
United Kingdom revenue was down 4.8% and EBITDAR, which is essentially earnings before interest, tax, depreciation and amortisation, was down 4.6%.
France revenue was down 1.1% and EBITDAR was down 5.8%.
The UK and France are key parts of the business, so it was worrying to see that both European operations went backwards in terms of revenue and profit. The company said that it was experiencing pricing constraints and volume pressures.
Ramsay’s Managing Director, Craig McNally, said that in the UK a positive tariff adjustment would take affect from 1 April 2018. He said that NHS demand management strategies were currently impacting volumes ‘significantly’.
He also said that Ramsay’s French operations would undertake a significant centralisation programme for non-core hospital functions such as finance, administration and HR. Once implemented, it will result in good savings each year.
Is it a buy after the result?
Ramsay is one of the highest quality businesses on the ASX. It has excellent tailwinds thanks to the ageing populations in the countries it operates in. It is always investing for growth with smaller projects and it’s also looking to expand into another geographical area.
The company’s price/earnings ratio has been coming down over the past 18 months as the share price decreases but its core earnings increases.
I believe that Ramsay will be a very good long-term hold at the current price, it’s trading at 24x FY17’s earnings. I’d be happy to buy today and hold for the next decade. It also helps that it has a grossed-up dividend yield of 3.16%.
Along with Ramsay, these top stocks would also make excellent long-term buys at today’s prices.
For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..
But knowing which blue chips to buy, and when, can be fraught with danger.
The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."
Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.
The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.
Click here to claim your free report.
Motley Fool contributor Tristan Harrison owns shares of HEALTHSCPE DEF SET and Ramsay Health Care Limited. The Motley Fool Australia has recommended Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.